Details for New Drug Application (NDA): 062659
✉ Email this page to a colleague
NDA 062659 describes CLAFORAN, which is a drug marketed by Sanofi Aventis Us and Sterimax and is included in three NDAs. Additional details are available on the CLAFORAN profile page.
The generic ingredient in CLAFORAN is cefotaxime sodium. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cefotaxime sodium profile page.
The generic ingredient in CLAFORAN is cefotaxime sodium. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cefotaxime sodium profile page.
Summary for 062659
| Tradename: | CLAFORAN |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | cefotaxime sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062659
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 1GM BASE/VIAL | ||||
| Approval Date: | Jan 13, 1987 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Jan 13, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
